Cihan Atila
Cihan Atila, MD, PhD is an expert in Endocrinology at University Hospital of Basel (Switzerland). As of October 2026, ScienceLeadR ranks Cihan Atila in the top 1% of experts worldwide for Diabetes Insipidus and Pituitary Diseases. Cihan Atila has authored 67 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 4 of them ongoing. SLR score: 437 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Nephrology - Neurology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2020 - 2026
Number : 67
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study. PMID 42835423 — arginine vasopressin, diabetes insipidus, neurogenic, adrenal insufficiency, deamino arginine vasopressin, pituitary diseases, arginine, case-control studies, neoplasms, recycling, hypothyroidism, diagnosis, pituitary neoplasms | J Endocr Soc | 2026 | 0 |
| ARGININE VASOPRESSIN DEFICIENCY: TOWARDS A BETTER CHARACTERIZATION. PMID 42677919 — arginine vasopressin, polydipsia, diabetes insipidus, neurogenic, deamino arginine vasopressin, polydipsia, psychogenic, arginine, hyponatremia, therapeutics, polyuria, diabetes insipidus | Endocr Relat Cancer | 2026 | 0 |
| Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache. PMID 42405663 — headache, glial fibrillary acidic protein, biomarkers, nervous system diseases | Eur J Neurol | 2026 | 0 |
| Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Early Indicators of Osmotic Brain Stress in Hyponatremia and Its Correction. PMID 42299484 — glial fibrillary acidic protein, hyponatremia, stress, physiological, brain, biomarkers, hormones | Eur J Endocrinol | 2026 | 0 |
| Oxytocin substitution therapy in patients with AVP deficiency (central diabetes insipidus): study protocol of a double-blind, randomised placebo-controlled trial. PMID 42082227 — diabetes mellitus, diabetes insipidus, neurogenic, emotions, oxytocin, therapeutics, diabetes insipidus | BMJ Open | 2026 | 0 |
Clinical Studies 10
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Circulating Oxytocin Changes in Response to MDMA vs Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls NCT07555132 — n-methyl-3,4-methylenedioxyamphetamine, autism spectrum disorder, placebos, autistic disorder, capsules, oxytocin, mannitol | N/A | Not yet recruiting | 2026 |
| Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment NCT07045935 — glucose tolerance test, prolactinoma, hyperprolactinemia, dopamine, tablets, cabergoline, prolactin, therapeutics, dopamine agonists | Phase 4 | Recruiting | 2025 |
| The PROMISE Survey NCT06936813 — prolactinoma, neoplasms, physicians, therapeutics, pituitary neoplasms | N/A | Active not recruiting | 2025 |
| Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus NCT06036004 — diabetes mellitus, arginine vasopressin, chlorobutanol, diabetes insipidus, neurogenic, arginine, nasal mucosa, respect, solutions, oxytocin, nasal sprays, therapeutics, mucous membrane, absorption, diabetes insipidus | Phase 2 | Recruiting | 2024 |
LeadR Networks
Main global connection map